drugset / Trial / NCT02761486

Effect of Aspirin on Gut Microbiome

NCT02761486

Phase 1 Completed 50 enrolled University of Minnesota
RandomizedParallel-groupQuadruple-blindBasic science

Summary

Regular use of aspirin may reduce the incidence of colorectal cancer (CRC). However, it is unclear through which mechanism aspirin exerts its effect, in whom it decreases CRC risk and in whom it causes side effects. Recently, the imbalanced gut microbiome was linked to inflammation and CRC risk. The main hypothesis for this study is that aspirin may decrease CRC risk via targeting the gut microbiome. The study will be a randomized placebo-controlled double-blinded design, recruiting 50 healthy subjects, 50-75 years old, from the PRospective Evaluation of SEPTin 9 (PRESEPT) cohort living in the greater Twin Cities area, who will receive either aspirin or placebo for 6 weeks.

Timeline

Start
2016-08
Primary completion
2018-06-01
Completion
2018-08-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 325 mg

Indications

No indication recorded.